Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 5Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Carcinoid Tumor 1Advanced Lung Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

gallium Ga 68 dotatate 3Specimen Handling 3Temozolomide 2Radiotherapy 2Magnetic Resonance Spectroscopy 26-fluorodopamine 2tipifarnib 1talazoparib 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1guadecitabine 1fostamatinib 1fluorodopa F 18 1Tamoxifen 1Surgical Procedures, Operative 1Ritonavir 1Oxaliplatin 1Nivolumab 1Leucovorin 1Ipilimumab 1Indinavir 1Fluorodeoxyglucose F18 1Floxuridine 1Doxorubicin 1Contrast Media 1Cisplatin 1CTLA-4 Antigen 1Biopsy 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pheochromocytoma × lutetium Lu 177 dotatate × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡